These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Influence of donor microbiota on the severity of experimental graft-versus-host-disease. Tawara I; Liu C; Tamaki H; Toubai T; Sun Y; Evers R; Nieves E; Mathewson N; Nunez G; Reddy P Biol Blood Marrow Transplant; 2013 Jan; 19(1):164-8. PubMed ID: 22982686 [TBL] [Abstract][Full Text] [Related]
5. S1PR5 regulates NK cell responses in preventing graft-versus-host disease while preserving graft-versus-tumour activity in a murine allogeneic haematopoietic stem cell transplantation model. Wang F; Zhao S; Gu Z; Zhao X; Yang N; Guan L; Liu T; Wang L; Fang S; Zhu C; Luo L; Li M; Wang L; Gao C Hematol Oncol; 2020 Feb; 38(1):89-102. PubMed ID: 31465552 [TBL] [Abstract][Full Text] [Related]
6. An epithelial target site in experimental graft-versus-host disease and cytokine-mediated cytotoxicity is defined by cytokeratin 15 expression. Whitaker-Menezes D; Jones SC; Friedman TM; Korngold R; Murphy GF Biol Blood Marrow Transplant; 2003 Sep; 9(9):559-70. PubMed ID: 14506658 [TBL] [Abstract][Full Text] [Related]
7. Topical neurokinin-1 receptor antagonist Fosaprepitant ameliorates ocular graft-versus-host disease in a preclinical mouse model. Lasagni Vitar RM; Bonelli F; Atay A; Triani F; Fonteyne P; Di Simone E; Rama P; Mondino A; Ferrari G Exp Eye Res; 2021 Nov; 212():108825. PubMed ID: 34740637 [TBL] [Abstract][Full Text] [Related]
8. Immunohistology and immunocytology of human T-cell chimerism and graft-versus-host disease in SCID mice. Hoffmann-Fezer G; Gall C; Zengerle U; Kranz B; Thierfelder S Blood; 1993 Jun; 81(12):3440-8. PubMed ID: 8099506 [TBL] [Abstract][Full Text] [Related]
9. The Necroptosis Pathway Is Upregulated in the Cornea in Mice With Ocular Graft-Versus-Host Disease. Asai K; Lee HK; Sato S; Shimizu E; Jung J; Okazaki T; Ogawa M; Shimmura S; Tsubota K; Ogawa Y; Negishi K; Hirayama M Invest Ophthalmol Vis Sci; 2024 Aug; 65(10):38. PubMed ID: 39189995 [TBL] [Abstract][Full Text] [Related]
10. Recruitment of Donor T Cells to the Eyes During Ocular GVHD in Recipients of MHC-Matched Allogeneic Hematopoietic Stem Cell Transplants. Herretes S; Ross DB; Duffort S; Barreras H; Yaohong T; Saeed AM; Murillo JC; Komanduri KV; Levy RB; Perez VL Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2348-57. PubMed ID: 25655798 [TBL] [Abstract][Full Text] [Related]
11. Safety analysis of ex vivo-expanded canine natural killer cells in a xenogeneic mouse model of graft-versus-host disease. Kim CJ; Park SC; Lee SH; Lim YJ; Yoon M; Park JG; Baek YB; Cho KO; Hong JW; Shin DJ; Kim SK J Leukoc Biol; 2022 Feb; 111(2):439-450. PubMed ID: 33884654 [TBL] [Abstract][Full Text] [Related]
12. Antilymphocytic antibodies and marrow transplantation. XII. Suppression of graft-versus-host disease by T-cell-modulating and depleting antimouse CD3 antibody is most effective when preinjected in the marrow recipient. Mysliwietz J; Thierfelder S Blood; 1992 Nov; 80(10):2661-7. PubMed ID: 1358260 [TBL] [Abstract][Full Text] [Related]
13. Novel Scoring Criteria for the Evaluation of Ocular Graft-versus-Host Disease in a Preclinical Allogeneic Hematopoietic Stem Cell Transplantation Animal Model. Perez VL; Barsam A; Duffort S; Urbieta M; Barreras H; Lightbourn C; Komanduri KV; Levy RB Biol Blood Marrow Transplant; 2016 Oct; 22(10):1765-1772. PubMed ID: 27492793 [TBL] [Abstract][Full Text] [Related]
15. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. Zhang Y; McCormick LL; Desai SR; Wu C; Gilliam AC J Immunol; 2002 Mar; 168(6):3088-98. PubMed ID: 11884483 [TBL] [Abstract][Full Text] [Related]
16. Lacrimal gland involvement in graft-versus-host disease: a murine model. Hassan AS; Clouthier SG; Ferrara JL; Stepan A; Mian SI; Ahmad AZ; Elner VM Invest Ophthalmol Vis Sci; 2005 Aug; 46(8):2692-7. PubMed ID: 16043840 [TBL] [Abstract][Full Text] [Related]
17. Lymphocytes with a CD4+ CD8- CD3- phenotype are effectors of experimental cutaneous graft-versus-host disease. Sakamoto H; Michaelson J; Jones WK; Bhan AK; Abhyankar S; Silverstein M; Golan DE; Burakoff SJ; Ferrara JL Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10890-4. PubMed ID: 1835792 [TBL] [Abstract][Full Text] [Related]
18. Ocular Surface and Tear Film Characteristics in a Sclerodermatous Chronic Graft-Versus-Host Disease Mouse Model. He J; Yamane M; Shibata S; Fukui M; Shimizu E; Yano T; Mukai S; Kawakami Y; Li S; Tsubota K; Ogawa Y Cornea; 2018 Apr; 37(4):486-494. PubMed ID: 29341972 [TBL] [Abstract][Full Text] [Related]
19. Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target. Sato M; Storb R; Loretz C; Stone D; Mielcarek M; Sale GE; Rezvani AR; Graves SS Transplantation; 2013 Jul; 96(1):34-41. PubMed ID: 23694952 [TBL] [Abstract][Full Text] [Related]
20. Ocular surface system alterations in ocular graft-versus-host disease: all the pieces of the complex puzzle. Giannaccare G; Pellegrini M; Bernabei F; Scorcia V; Campos E Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1341-1351. PubMed ID: 30944986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]